Pfizer explores sale of hospital drugs unit, sources say

Exclusive: Pfizer explores sale of hospital drugs unit, sources say
Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.
Pfizer reportedly eyeing sale of hospital drugs unit
Pfizer (NYSE:PFE) has hired Goldman Sachs to gauge initial buyer interest as part of an attempt to sell its hospital drugs unit, Pfizer Hospital, potentially worth a few billion dollars, Reuters reported Tuesday,
Pfizer considers divestiture of hospital drugs business
"Pfizer considers divestiture of hospital drugs business" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Pfizer exploring sale of hospital drugs unit, Reuters reports
Pfizer (PFE) is exploring the sale of its hospital drugs unit, now called Pfizer Hospital, which was formed after Pfizer bought Hospira for
Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports
Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from activist investor Starboard Value. The unit, formed after Pfizer's $17 billion Hospira acquisition in 2015,
Pfizer's Strategic Shift: Potential Sale of Hospital Drugs Unit
Pfizer is considering selling its hospital drugs unit, known as Pfizer Hospital, to reduce debt and streamline operations. This move follows pressure from activist investors and a history of large acquisitions.
Pfizer said to be exploring sale of hospital drugs unit, Reuters reports
Pfizer (PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, Reuters’ Anirban Sen reports, citing people familiar with the matter.
FiercePharma1d
Pfizer explores sale of hospital drugs unit amid activist investor's call for accountability: Reuters
After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to ...
devdiscourse17h
Pharma Updates: Amgen Overcomes Concerns, AstraZeneca Expands, and Pfizer Considers Sale
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...
STAT1d
Pharmalittle: We’re reading about an Amgen data controversy, J&J suing the feds, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...
Becker's Hospital Review1d
9 drugs now in shortage
Dextran low molecular weight injection: Pfizer is reporting a shortage of Dextran 40 due to manufacturing delays. The 500-milliliter, 5% dextrose presentations, both in 12-unit cartons, are ...
Yahoo Finance23d
Starboard Value CEO says Pfizer's board should hold management accountable
NEW YORK (Reuters) -Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs ... producing profitable new drugs. "We measure success ...